TB-500
Also known as: Thymosin beta-4 fragment, Ac-LKKTETQ, N-acetyl-LKKTETQ, Tβ4 fragment (17-23), Thymosin beta-500
Synthetic peptide fragment (actin-binding / tissue repair peptide); derived from the active site of thymosin beta-4 (Tβ4)
What it is
TB-500 is a peptide people use to speed recovery from tendon, muscle, and wound injuries, and to support athletic performance. It works by activating pathways that promote the formation of new blood vessels and tissue repair. Not FDA-approved; banned by WADA; sold as a gray-market research compound.
The scientific side
TB-500 is the synthetic N-terminal acetylated heptapeptide fragment (Ac-LKKTETQ) corresponding to residues 17–23 of thymosin beta-4 (Tβ4), representing the actin-binding active site of the parent protein. In its unacetylated form (LKKTETQ), biological functions include actin binding, dermal wound healing, angiogenesis, and skin repair. TB-500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition, and decreased inflammation. Reviews describe TB-500 as promoting angiogenesis and tissue repair in preclinical models, and acting via integrin-mediated extracellular matrix remodeling and fibroblast activation (PMID 41490200; PMID 41476424). Metabolic studies found that the primary metabolites are Ac-LK (highest concentration at 0–6 h) and Ac-LKK (detectable up to 72 h), and suggest that previously reported wound-healing activity may be attributable to the metabolite Ac-LKKTE rather than the parent compound itself.
Class: Synthetic peptide fragment (actin-binding / tissue repair peptide); derived from the active site of thymosin beta-4 (Tβ4)
At a glance
| What it is | A synthetic 7-amino-acid peptide, Ac-LKKTETQ: residues 17-23 of the natural protein thymosin beta-4, with an acetyl group added. |
|---|---|
| FDA status | Not approved for any use. An FDA advisory committee voted 8-6 in July 2026 to let compounding pharmacies make it; that vote is a recommendation only. |
| Used for | Muscle, tendon and wound recovery, based on animal and cell studies of thymosin beta-4. |
| Human evidence | None for TB-500 itself. Human trials exist only for full-length thymosin beta-4, a different, larger molecule. |
| Half-life | Not measured. In rats, a breakdown product stayed detectable in urine for up to 72 hours. |
| Banned in sport | Yes. WADA names it under S2.3 (growth factors), prohibited at all times. |
What is TB-500?
TB-500 is a synthetic peptide with the sequence Ac-LKKTETQ. It copies a short stretch, residues 17 to 23, of thymosin beta-4, a 43-amino-acid protein found in almost every cell. Equine doping chemists describe it as "a synthetic version of an active region of thymosin beta4".
The name causes confusion: TB-500 is often sold as if it were thymosin beta-4, and some vendors describe it as 17 amino acids, a mix-up with the residue numbers. Studies of full-length thymosin beta-4 do not tell you what the 7-amino-acid fragment does in people. It is commonly stacked with BPC-157.
How does it work?
The LKKTETQ stretch is the part of thymosin beta-4 that binds actin, a protein cells use to move and change shape. In cell and animal studies this region promoted cell migration, new blood vessel growth and wound healing.
Whether the short fragment reproduces the effects of the full protein in people is unknown. A 2024 rat study found TB-500 is quickly cut into smaller pieces; the authors suggested one of them may carry the wound-healing activity.
Pharmacokinetics
| Half-life | Not measured for TB-500 (no human or animal half-life published) |
|---|---|
| Metabolism | Rapidly cut into smaller fragments; Ac-LK was the main metabolite in rats (animal data) |
| Clearance | Breakdown product Ac-LKK detectable in rat urine for up to 72 hours (animal data) |
| Route | No human data for TB-500; sold for injection under the skin or into muscle |
Is it FDA-approved?
No. TB-500 has never been approved for any use, and no company has tested it in a human trial.
FDA placed it on its list of compounding substances with significant safety risks ("Category 2") in September 2023. FDA wrote that it "has not identified any human exposure data" for it and flagged immunogenicity and impurity risks. By April 2026 FDA listed it as nominated but withdrawn. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted 8-6, with 1 abstention, to recommend it for the list of substances compounding pharmacies may use. That vote is not binding; FDA would still need to complete rulemaking.
- WADA: S2.3 Growth factors and growth factor modulators ("Thymosin-ß4 and its derivatives e.g. TB-500"; prohibited at all times)
History
Thymosin beta-4 is a natural protein that binds actin inside cells. Research groups mapped which short stretches of it carry its effects; a 2010 study tied the 17-23 region to cell migration, blood vessel growth and wound healing.
The full protein went into clinical development, including eye drops and an IV form. TB-500, the short synthetic fragment, took a different path: it appeared in horse racing, where a 2012 paper described a doping test for it, and then in the human grey market for recovery.
Regulatory timeline
- September 29, 2023FDA places "thymosin beta-4, fragment (LKKTETQ)" in Category 2 (503A), citing immunogenicity and impurity risks and no human exposure data. Source
- April 2026FDA lists it under "nominated but withdrawn", so it is no longer in Category 2. FDA's page was updated April 22, 2026. Source
- July 23, 2026FDA's Pharmacy Compounding Advisory Committee votes 8-6, with 1 abstention, to recommend TB-500 for the 503A bulks list. The vote is a non-binding recommendation. Source
- As of October 2026Still not FDA-approved. Compounding would still require FDA to accept the recommendation and complete rulemaking. Source
Side effects
There are no human side-effect data for TB-500. Trials of full-length thymosin beta-4 given by IV to healthy volunteers reported no dose-limiting toxicities or serious adverse events, but that is a different molecule, given by a different route.
Two concerns come up repeatedly. FDA flagged a risk of immune reactions from aggregation and impurities. And in a 2003 mouse study, cancer cells engineered to overproduce thymosin beta-4 formed larger tumors and more metastases with more blood vessels; whether injected TB-500 has any similar effect is unknown.
Who should not use it
- No established contraindications: TB-500 has never been through human trials.
- Competitive athletes: prohibited at all times under WADA S2.3.
- Active or past cancer: animal data link thymosin beta-4 to tumor blood vessel growth, so caution is reasonable.
- Pregnancy and breastfeeding: not studied.
No human trial of TB-500 has been published. Safety data cited online come from trials of full-length thymosin beta-4.
What does the research show?
No clinical trial of TB-500 has been published. The human trials people cite used full-length thymosin beta-4. Two phase 1 studies of IV thymosin beta-4 in healthy volunteers (40 and 84 people) found it well tolerated. A small phase 3 trial of thymosin beta-4 eye drops for a corneal healing disorder found complete healing in 6 of 10 treated patients versus 1 of 8 on placebo, a result that just missed statistical significance (p = 0.0656).
For TB-500 itself, the published work is analytical and animal-based: methods to detect it in horses, and a rat study tracking how it breaks down.
Studied for
- Wound healing and cell migration (cell and animal studies)
- Doping detection in horses (analytical studies)
- Full-length thymosin beta-4, not TB-500: corneal healing, skin wounds, heart injury (human trials)
FAQ
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is a 43-amino-acid protein. TB-500 is a 7-amino-acid synthetic copy of one region of it (residues 17-23).
Sources: [1]
Has TB-500 been tested in humans?
No. The human trials people cite tested full-length thymosin beta-4, a different and much larger molecule. FDA says it has not identified any human exposure data for TB-500.
Is TB-500 FDA-approved?
No, not for any use. The July 2026 advisory committee vote was about compounding, not approval, and it was a recommendation only.
Sources: [5]
Can a compounding pharmacy make TB-500 now?
Not under the normal 503A route yet. FDA would have to accept the July 2026 recommendation and finish proposed and final rulemaking before adding it to the bulks list.
Is TB-500 banned in sport?
Yes. The 2026 WADA Prohibited List names "Thymosin-ß4 and its derivatives e.g. TB-500" under S2.3, prohibited at all times.
Sources: [11]
Can TB-500 cause cancer?
There is no evidence it does. The concern comes from a 2003 mouse study where cancer cells overproducing thymosin beta-4 formed larger, more vascular tumors. Nobody has tested whether injected TB-500 does anything similar.
Sources: [10]
How long does TB-500 stay in the body?
Its half-life has not been measured. In rats it was quickly broken down, and one fragment stayed detectable in urine for up to 72 hours.
Sources: [4]
Citations
- Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma. J Chromatogr A 2012. PMID 23084823
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J 2010. PMID 20179146
- Rahaman KA, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats. J Chromatogr B 2024. PMID 38382158
- Steinzor P. FDA panel backs 6 peptides for compounding. AJMC, July 31, 2026. ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
- FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee. fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- Sosne G, et al. 0.1% RGN-259 (thymosin beta4) ophthalmic solution in neurotrophic keratopathy: a randomized phase III trial. Int J Mol Sci 2022. PMID 36613994
- Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci 2010. PMID 20536472
- Wang X, et al. A first-in-human phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med 2021. PMID 34346165
- Cha HJ, et al. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst 2003. PMID 14625258
- World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
Sources
- Ho 2012. Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma. J Chromatogr A 2012. pubmed.ncbi.nlm.nih.gov/23084823
- Sosne 2010. Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J 2010. pubmed.ncbi.nlm.nih.gov/20179146
- Rahaman 2024. Rahaman KA, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats. J Chromatogr B 2024. pubmed.ncbi.nlm.nih.gov/38382158
- Ruff 2010. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci 2010. pubmed.ncbi.nlm.nih.gov/20536472
- Wang 2021. Wang X, et al. A first-in-human phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med 2021. pubmed.ncbi.nlm.nih.gov/34346165
- Sosne 2022. Sosne G, et al. 0.1% RGN-259 (thymosin beta4) ophthalmic solution in neurotrophic keratopathy: a randomized phase III trial. Int J Mol Sci 2022. pubmed.ncbi.nlm.nih.gov/36613994
- Cha 2003. Cha HJ, et al. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst 2003. pubmed.ncbi.nlm.nih.gov/14625258
- FDA. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA (2024 archive). FDA: the same page as archived September 28, 2024. web.archive.org/web/20240928064141/https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- AJMC, July 2026. Steinzor P. FDA panel backs 6 peptides for compounding. AJMC, July 31, 2026. ajmc.com/view/fda-panel-backs-6-peptides-for-compounding
- FDA PCAC, July 2026. FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee. fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- WADA. World Anti-Doping Agency: Prohibited List 2026 (copy hosted by SEGAS). segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf
Modified Forms
The following chemical variants are structurally derived from this peptide. They are documented here rather than on separate pages.
TB-500 Fragment (17-23) — LKKTETQ
TB-500 Fragment (17-23), sequence LKKTETQ, is the seven-amino-acid actin-binding domain extracted from full TB-500 (Thymosin Beta-4, 43 amino acids). The fragment retains G-actin sequestering activity, which drives cell migration underlying wound healing and angiogenesis, but lacks the remaining 36 amino acids of the parent protein. Molecular weight is approximately 829 Da versus 4963 Da for full TB-500. Animal studies confirm wound healing activity comparable to the full peptide in dermal wound models (PMID: 12581423, 17001601). The fragment is detected in equine anti-doping samples at 10 mg doses (PMID: 23084823). All evidence is preclinical. The form is typically supplied as N-acetylated LKKTETQ (Ac-LKKTETQ).
How dosing differs: A single 10 mg dose was detected in equine anti-doping research (PMID: 23084823). No human dose-finding studies exist. Community dosing typically mirrors full TB-500 protocols (500 mcg–2 mg subcutaneous), though fragment-specific human data is absent. The smaller molecular weight may affect pharmacokinetics relative to the full peptide.
Key differences from parent: Smaller molecule (~829 Da vs ~4963 Da) with potentially improved tissue penetration and lower synthesis cost. Retains the actin-sequestering LKKTETQ core but lacks the full parent sequence's additional structural and signalling elements. Fragment-specific PMIDs confirm independent wound healing activity in rodent and ophthalmic models.
Form-specific studies: PMID 12581423 PMID 17001601 PMID 23084823 PMID 38382158 PMID 41359360
Administration & storage
- Administration
- Intraperitoneal injection — used in rat Achilles tendon study (PMID: 42542926)Subcutaneous injection — reported in equine administration study (PMID: 23318763)
- Storage
- One anti-doping study noted that −20°C was found to be the appropriate storage temperature for peptides including TB-500 in urine for sports drug testing purposes. No other storage conditions for TB-500 preparations are described in the reviewed abstracts.
- Cautions
- TB-500 has no established human safety profile; reviewed literature describes it as an unapproved compound with scarce rigorous human safety data and potential for serious patient harm.,Unregulated injectable peptides, including TB-500, carry risks of product contamination, manufacturing impurities, inaccurate dosing, pathological angiogenesis, and carcinogenesis.,Compounded or gray-market peptide preparations may not meet pharmaceutical manufacturing standards, increasing risk of impurities (PMID: 42757290; PMID: 41966639).,TB-500 is a WADA-prohibited substance; use by competitive athletes may result in anti-doping rule violations (PMID: 41476424; PMID: 26578461).,Sterile technique is essential for any injectable preparation to reduce infection risk.
Legal & regulatory status
Not approved for human use by the FDA. Reviewed literature describes TB-500 as an unapproved, investigational compound operating in a 'gray market'. One review notes most of these therapies remain unapproved by the U.S.…
Listed as a prohibited substance on the WADA Prohibited List. Multiple anti-doping publications describe TB-500 as a WADA-prohibited substance and doping-relevant compound (PMID: 26578461; PMID: 41476424). Reviewed…
Not stated in reviewed literature — requires manual verification
What it's studied for
- Tendon healing / Achilles tendon repair Animal studies only
- In a rat Achilles tendon transection model (n=8/group), TB-500 at 60 µg/kg/day IP for 4 weeks produced significantly higher maximum load to failure versus controls (p<0.05), significantly lower Bonar scores (p=0.016) and Movin scores (p=0.017), and altered collagen type I/III distribution consistent with matrix maturat PMID 42542926 Biçer O et al. Joint Diseases and Related Surgery (2026)
- Wound healing / angiogenesis / tissue repair Mixed
- In vitro fibroblast wound healing assay: no cytotoxicity found for parent TB-500 or its metabolites; metabolite Ac-LKKTE showed significant wound healing activity compared to control, suggesting that wound-healing activity attributed to TB-500 in the literature may be due to this metabolite. PMID 38382158 Rahaman KA et al. Journal of Chromatography B (2024)
- Narrative review concludes TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models; human orthopaedic data are lacking. PMID 41476424 Mayfield CK et al. American Journal of Sports Medicine (2026)
- Review notes TB-500 promotes angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation; preclinical studies promising but lack of clinical trials noted. PMID 41490200 Rahman OF et al. JAAOS Global Research & Reviews (2026)
- Narrative review summarizes TB-500's proposed mechanisms in tissue repair and chronic pain; notes evidence in humans is limited and the therapy remains unapproved by the FDA. PMID 42635865 Luansritisakul C et al. Current Pain and Headache Reports (2026)
- Musculoskeletal recovery and athletic performance Animal studies only
- Scoping review: 67% of identified publications used preclinical animal models. TB-500 demonstrated unique mechanisms with promising but variable effects on tendon, muscle, bone, and ligament healing in animal models. Human clinical studies were limited, lacking robust controls. Benefits for musculoskeletal recovery rem PMID 42578445 Tewari K et al. American Journal of Sports Medicine (2026)
- Narrative review: TB-500 demonstrates favorable tissue repair outcomes in animal models, but rigorous human safety data are scarce and there is potential for serious harm. Describes TB-500 as operating in a 'gray market' outside regulatory oversight. PMID 41966639 Mendias CL & Awan TM. Sports Medicine (2026)
- Healthy aging / gerontology Animal studies only
- Narrative review identifies TB-500 among peptides with potential applications in tissue repair relevant to aging; non-approved peptides show promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation. PMID 42021992 Mavrych V et al. Frontiers in Aging (2026)
Safety signals
- No established human safety profile; rigorous human safety data are scarce and there is potential for serious harm to patients using unapproved TB-500 PMID 41966639
- Risk of product contamination, manufacturing impurities, and inaccurate dosing from unregulated gray-market sources PMID 42757290
- Potential for pathological angiogenesis and carcinogenesis associated with unapproved angiogenic peptides including TB-500 PMID 42757290
- No cytotoxicity observed for parent TB-500 or its metabolites in in vitro fibroblast assays, but biological effects of TB-500 in vivo have not been fully documented PMID 38382158
- Lack of long-term safety data and systematic clinical validation for TB-500 as a non-approved peptide PMID 42021992
Contraindications
- No specific contraindications described in the reviewed literature. Use in competitive sports contexts is prohibited under WADA regulations. PMID 41476424
Protocol
2.0-2.5 mg subcutaneous injection, twice per week. Cycle: 4-6 weeks (loading phase).
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Intraperitoneal | 60 µg/kg/day | 4 weeks | animal | Research PMID 42542926 |
| Not explicitly stated (post-administration samples collected from horses) | Single dose containing 10 mg of N-acetylated LKKTETQ | Single administration | animal | Research PMID 23084823 |
| Subcutaneous | 10 mg N-acetylated LKKTETQ | Single administration | animal | Research PMID 23318763 |
| subcutaneous injection | 2.0-2.5 mg | twice per week · 4-6 weeks (loading phase) | biohackers and athletes seeking accelerated soft-tissue injury recovery | [Community] |
| subcutaneous injection | 2.0-2.5 mg | once per week · 4-8 weeks (maintenance phase) | biohackers and athletes post-loading phase or for injury maintenance | [Community] |
| subcutaneous injection | 2.0-2.5 mg | once every 2 weeks · ongoing / indefinite | biohackers using TB-500 for anti-aging, general recovery, or injury prevention | [Community] |
| subcutaneous injection | 5.0 mg | twice per week · 4 weeks (aggressive loading) | athletes or bodybuilders with acute or severe soft-tissue injuries | [Community] |
| subcutaneous injection | 5.0 mg | once per week · 4-6 weeks | athletes with moderate-to-severe musculoskeletal injuries | [Community] |
| subcutaneous injection | 750 mcg | daily · 4-6 weeks | biohackers preferring daily microdose protocols for systemic distribution | [Community] |
| intramuscular injection | 2.0-2.5 mg | twice per week · 4-6 weeks (loading) | athletes preferring IM administration for localized muscle injuries | [Community] |
| subcutaneous injection | 2.0-2.5 mg | twice per week · 4-6 weeks | biohackers stacking TB-500 with BPC-157 for synergistic tissue repair | [Community] |
| subcutaneous injection | 2.0 mg | once per week · 12 weeks | older biohackers (40+) using TB-500 for longevity, cardiovascular health, and systemic anti-inflammatory effects | [Community] |
| subcutaneous injection | 1.0 mg | twice per week · 4-6 weeks | beginners or cautious biohackers starting with a conservative TB-500 protocol | [Community] |
The TB-500 + BPC-157 stack: what the one direct study found
TB-500 + BPC-157 is widely promoted online as a healing stack. The only published combination study — a rat Achilles tendon model (PMID: 42542926, 2026) — found TB-500 alone significantly improved outcomes, while the combination showed no additive benefit over either agent alone. No human trials on the combination exist.
Read our full blend review →Stacks and blends containing this peptide
All studies (14)
- PMID 38382158 Mixed
Wound healing / angiogenesis / tissue repair - PMID 41476424 Mixed
Wound healing / angiogenesis / tissue repair - PMID 41490200 Mixed
Wound healing / angiogenesis / tissue repair - PMID 42635865 Mixed
Wound healing / angiogenesis / tissue repair - PMID 23084823
Single dose containing 10 mg of N-acetylated LKKTETQ Not explicitly stated (post-administration samples collected from horses) (animal) - PMID 23318763
10 mg N-acetylated LKKTETQ Subcutaneous (animal) - PMID 25469748
- PMID 26578461
- PMID 27569051
- PMID 41966639 Animal studies only
Musculoskeletal recovery and athletic performance - PMID 42021992 Animal studies only
Healthy aging / gerontology - PMID 42542926 Animal studies only
Tendon healing / Achilles tendon repair - PMID 42578445 Animal studies only
Musculoskeletal recovery and athletic performance - PMID 42757290
Risk of product contamination, manufacturing impurities, and inaccurate dosing from unregulated gray-market sources
Frequently asked
What is TB-500 and where does it come from?
TB-500 is a synthetic heptapeptide (Ac-LKKTETQ) corresponding to residues 17–23 of thymosin beta-4 (Tβ4), which is the actin-binding active site of the parent protein. It is sometimes referred to as a 'fragment' of thymosin beta-4 (PMID 23084823; PMID 38382158). It is produced synthetically and has been identified as the key ingredient in a veterinary preparation.
What does TB-500 do / what is it used for?
In preclinical models, TB-500 has been studied for promoting angiogenesis, wound healing, collagen deposition, keratinocyte migration, and tissue repair (PMID 23084823; PMID 41476424). An animal study showed improved tendon biomechanics and histopathology after Achilles tendon injury in rats. Importantly, there are no robust human clinical trials supporting these uses, and benefits in humans remain unsubstantiated (PMID 42578445; PMID 41966639).
What dose of TB-500 should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: the only dose reported in a published animal study was 60 µg/kg/day administered intraperitoneally in rats for 4 weeks, and a single equine study used 10 mg subcutaneously. No human dosing data exist in the reviewed literature, and one review explicitly states that 'information regarding the indications, dosing, frequency, and duration of treatment remains unknown'.
Is TB-500 FDA-approved?
No. Reviewed literature consistently describes TB-500 as an unapproved compound. One review states it is among peptides that 'remain unapproved by the U.S. Food and Drug Administration (FDA)', and another describes it as operating in a 'gray market' outside regulatory oversight. Manual verification of current FDA regulatory status is recommended.
Is TB-500 banned in sports?
Yes. Multiple reviewed publications describe TB-500 as a WADA-prohibited substance. One review explicitly states that TB-4 and its derivative TB-500 'remain banned substances in sports'. Anti-doping detection methods for TB-500 in urine and plasma have been developed and validated for both human and equine sports (PMID 26578461; PMID 23084823; PMID 25469748).
Is TB-500 safe for humans?
Human safety data are scarce. Reviewed literature states that 'rigorous human safety data are scarce, and there is potential for serious harm to patients'. Risks associated with unregulated injectable peptides including TB-500 include product contamination, manufacturing impurities, inaccurate dosing, pathological angiogenesis, and carcinogenesis. Non-approved peptides like TB-500 lack long-term safety data and systematic clinical validation. No cytotoxicity was observed in an in vitro fibroblast study, but this does not establish human safety.
Can I combine TB-500 with BPC-157 or other peptides?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: one rat study examined TB-500 (60 µg/kg/day IP), BPC-157 (10 µg/kg/day IP), and their combination on Achilles tendon repair. The combination did not confer additional benefit over either agent alone, possibly reflecting convergence on shared downstream pathways. No human combination studies were identified in the reviewed literature.
Where can I buy TB-500?
I don't recommend vendors or sources. Please consult a licensed provider.
Can TB-500 help with my [specific injury or condition]?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. What the literature shows is that TB-500 has demonstrated tissue repair and tendon healing effects in preclinical animal models (PMID 42542926; PMID 41476424), but human clinical trials are absent and claimed benefits in humans remain unsubstantiated (PMID 42578445; PMID 41966639).
How is TB-500 metabolized and how long can it be detected?
In vitro and rat studies found that the primary metabolite of TB-500 (Ac-LKKTETQ) is Ac-LK, which reached the highest concentration at 0–6 hours after dosing, while Ac-LKK was detectable as a long-term metabolite up to 72 hours in rats. Human kidney microsomes and liver S9 fractions showed high metabolic activity against TB-500 in vitro. In equine anti-doping studies, the parent compound and its metabolite Ac-LK were detected in plasma and urine following a single subcutaneous dose. Human pharmacokinetic data are not available in the reviewed literature.